Skip to main content

Want a detailed portfolio tracker?

SOPHiA Genetics (SOPH) EBITDA (2020 - 2026)

SOPHiA Genetics (SOPH) EBITDA from Mar 31, 2020 to Mar 31, 2026. The TTM SOPHiA Genetics (SOPH) EBITDA is -$66M. You can adjust inflation or export chart.

All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.

Annual EBITDA

Quarterly EBITDA

SOPHiA Genetics (SOPH) EBITDA CAGR table

PeriodCAGR
1 Year TTM+39.10%
3 Years TTM-4.10%
5 Years TTM+9.33%
All Time TTM+9.33%

Annual EBITDA change of SOPHiA Genetics (SOPH)

YearEBITDAChange
2026-$15M-76.34%
2025-$61M+20.96%
2024-$51M-27.04%
2023-$70M-14.50%
2022-$81M+17.52%
2021-$69M+82.26%
2020-$38M+23.58%
2019-$31MN/A

Comparison SOPHiA Genetics (SOPH) five years EBITDA CAGR with competitors

SOPHiA Genetics (SOPH) five years EBITDA CAGR is 9.33%.

TickerNamefive years EBITDA CAGRUpside
OPRXOptimizeRx Corp77.72%+733.18%
CCLDCareCloud Inc73.90%+692.17%
CCLDOCareCloud Inc73.90%+692.17%
SYSo-Young International Inc39.98%+328.56%
DOCSDoximity Inc - Class A32.10%+244.10%
HQYHealthequity Inc26.05%+179.29%
VEEVVeeva Systems Inc - Class A25.30%+171.19%
HCATHealth Catalyst Inc20.13%+115.84%
SDGRSchrodinger Inc18.03%+93.30%
PRVAPrivia Health Group Inc10.68%+14.44%
EVHEvolent Health Inc - Class A9.64%+3.31%
HSTMHealthstream Inc9.04%-3.11%
OMCLOmnicell Inc0.63%-93.27%
DRIODarioHealth Corp0.22%-97.65%